Workflow
塞力斯医疗科技集团股份有限公司2025年第五次临时股东会决议公告

Core Points - The company held its fifth extraordinary general meeting on October 9, 2025, with no resolutions being rejected [2][3] - The meeting was convened by the board of directors and chaired by Chairman Wen Wei, complying with relevant laws and regulations [3][4] - A significant resolution was passed regarding capital increase for a subsidiary and related party investment [5][6] Meeting Details - The meeting took place at the company's headquarters in Wuhan, China [2] - All nine current directors attended the meeting, along with the board secretary and other senior executives [4] Voting and Legal Oversight - The resolution regarding the subsidiary's capital increase was approved by more than half of the voting rights held by attending shareholders [6] - The meeting was witnessed by lawyers from Guohao Law Firm, confirming that the procedures and voting results were legal and valid [6] Convertible Bond Information - As of September 30, 2025, a total of 231.552 million yuan of "Saili Convertible Bonds" had been converted into ordinary shares, representing 9.3975% of the company's total share capital before conversion [8][16] - The total amount of unconverted convertible bonds as of the same date was 187.978 million yuan, accounting for 34.5987% of the total issuance [8][16] - During the third quarter of 2025, 229.833 million yuan of convertible bonds were converted, resulting in the issuance of 19.15182 million shares [8][15] Convertible Bond Issuance and Terms - The company issued 5.4331 million convertible bonds in August 2020, with a total value of 54.331 million yuan and a maturity of six years [10][11] - The initial conversion price was set at 16.98 yuan per share, with subsequent adjustments made to the conversion price over time [12][13][14]